COMP <GO>
UFPT vs ABBV // GROSS PROFIT MARGIN
UFP Technologies Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: UFPT 7
— ABBV 6
▲ GROSS PROFIT MARGIN LEADER: ABBV
LAST: $293.30 (+2.55%) • MKT CAP: $2.27B
gross-margins
28.30%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
gross-margins
70.20%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UFPT VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UFPT | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 28.30% | 70.20% | -41.90 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.90% | 29.00% | -15.10 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 25.7x | 33.3x | -7.60 | UFPT | /valuation <GO> |
| Free Cash Flow Yield | 4.05% | 3.47% | +0.58 | UFPT | /fcf-yield <GO> |
| Operating Margin | 15.30% | 24.60% | -9.30 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 11.30% | 6.90% | +4.40 | UFPT | /net-margins <GO> |
| Revenue Growth (YoY) | 19.50% | 8.60% | +10.90 | UFPT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.31 | 5.33 | +2.98 | UFPT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | UFPT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.0 | 65.1 | -21.06 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.0x | 113.1x | -85.10 | UFPT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.27B | $513.86B | -$511.59B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UFPT REV | ABBV REV | UFPT GROSS % | ABBV GROSS % | UFPT FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $602.8M | $61.16B | 28.3% | 70.2% | $91.9M | $17.82B |
| FY 2024 | $504.4M | $56.33B | 29.1% | 70.0% | $56.9M | $17.83B |
| FY 2023 | $400.1M | $54.32B | — | — | $41.3M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UFPT // BETA —
ABBV // BETA 1.15